Bristol Myers announces ‘positive’ results from Phase 3 SCOUT-HCM trial

Bristol Myers (BMY) Squibb announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos in the first study of a cardiac myosin inhibitor in adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The trial met its primary endpoint, demonstrating a statistically significant reduction from baseline in Valsalva left ventricular outflow tract gradient at Week 28 versus placebo, indicating Camzyos was effective in improving LVOT obstruction. Statistical significance was also met for multiple secondary endpoints, including those for clinically meaningful aspects of the disease. Safety results in the trial were consistent with the established safety profile of Camzyos in adults, and no new safety signals were reported in this new, younger population. The study continues with active treatment and long-term extension periods.